Engineered Transaminase Variants for Stable Chiral Amine Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Wild-type transaminases exhibit instability under industrially useful conditions, poor substrate recognition, and low stereoselectivity, leading to unfavorable reaction equilibria and low product yields in the production of chiral amine compounds.
Innovation Solution
Engineered transaminase polypeptides with specific amino acid residue differences, enhancing solvent and thermal stability, and improved stereoselectivity for the conversion of keto substrates to chiral amines, such as sitagliptin, under industrial conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type transaminases are used for chiral amine production, then the process is simple and cost-effective, but the enzyme exhibits instability under industrial conditions and poor substrate recognition leading to low product yields
Solution Approach 1:
The patent applies parameter changes by modifying specific amino acid residues at positions 85, 198, and 201 in the transaminase sequence to enhance enzyme stability and activity under industrial conditions while maintaining catalytic function for chiral amine production
Solution Approach 2:
The patent creates engineered transaminase variants that copy the essential catalytic features of wild-type enzymes while incorporating specific mutations to improve stability, substrate recognition, and product yield without completely redesigning the enzyme structure
2Manufacturing precision
If wild-type transaminases are used, then no engineering is needed, but stereoselectivity is low resulting in unfavorable reaction equilibria
Solution Approach 1:
The patent modifies specific amino acid parameters at positions 85, 198, and 201 to enhance stereoselectivity toward desired chiral amine products while simultaneously improving reaction efficiency and shifting equilibrium favorably toward product formation
Solution Approach 2:
The patent replaces the natural but insufficient stereoselectivity mechanism of wild-type transaminases with an engineered active site configuration that provides enhanced stereochemical discrimination and catalytic efficiency through specific residue substitutions
3Productivity
If engineered transaminase polypeptides are developed to improve stability and stereoselectivity, then product yield and enantiomeric excess increase, but the complexity of enzyme development and characterization increases
Solution Approach 1:
The patent systematically modifies specific amino acid parameters at key positions to achieve enhanced product yield and enantiomeric excess, using rational design based on structure-function relationships to minimize the complexity of development
Solution Approach 2:
The patent creates engineered variants that copy the essential catalytic mechanism of wild-type transaminases while incorporating targeted improvements, allowing for simplified development compared to de novo enzyme design while achieving superior productivity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered transaminases demonstrate enhanced activity, stability, and stereoselectivity, enabling efficient conversion of keto substrates to chiral amines with high enantiomeric excess, suitable for industrial-scale production of pharmaceutical compounds like sitagliptin.
Implementation Method 1
Transaminases (E.C. 2.6.1) catalyze the transfer of an amino group, a pair of electrons, and a proton from an amino donor compound to the keto group of an amino acceptor compound
Implementation Method 2
The transaminase catalyzes the transfer of the primary amine group of the amino donor compound (A) to the keto group of the amino acceptor compound (B)
Data Source
AI summary
The present disclosure provides engineered transaminase polypeptides useful for the synthesis of chiral amine compounds under industrially relevant conditions. The disclosure also provides polynucleotides encoding the engineered transaminase polypeptides, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases for the production of chiral amine compounds.